These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22299759)

  • 1. Assessing stakeholder opinion on relations between cancer patient groups and pharmaceutical companies in Europe.
    Leto di Priolo S; Fehervary A; Riggins P; Redmond K
    Patient; 2012; 5(2):127-39. PubMed ID: 22299759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study.
    Parker L; Fabbri A; Grundy Q; Mintzes B; Bero L
    BMJ; 2019 Dec; 367():l6694. PubMed ID: 31831471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.
    Kang SY; Bai G; Karas L; Anderson GF
    Am J Public Health; 2019 Apr; 109(4):559-561. PubMed ID: 30789768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.
    Fabbri A; Santos A; Mezinska S; Mulinari S; Mintzes B
    Int J Health Policy Manag; 2018 Jun; 7(6):504-509. PubMed ID: 29935127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.
    Rose SL; Highland J; Karafa MT; Joffe S
    JAMA Intern Med; 2017 Mar; 177(3):344-350. PubMed ID: 28114624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview study.
    Parsons S; Starling B; Mullan-Jensen C; Tham SG; Warner K; Wever K
    BMJ Open; 2016 Jan; 6(1):e008928. PubMed ID: 26743701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
    D'Hooghe T
    Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between medical residents and drug companies: a national survey after the Mediator® affair.
    Montastruc F; Moulis G; Palmaro A; Gardette V; Durrieu G; Montastruc JL
    PLoS One; 2014; 9(10):e104828. PubMed ID: 25279555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries.
    Mulinari S; Martinon L; Jachiet PA; Ozieranski P
    Health Policy; 2021 Jul; 125(7):915-922. PubMed ID: 34006392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conflicts of interest in medical school: missing policies and high need for student information at most German universities.
    Lieb K; Koch C
    GMS Z Med Ausbild; 2014; 31(1):Doc10. PubMed ID: 24575152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs.
    Mulinari S; Vilhelmsson A; Rickard E; Ozieranski P
    PLoS One; 2020; 15(6):e0235021. PubMed ID: 32579571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What patients think about promotional activities of pharmaceutical companies in Turkey.
    Semin S; Güldal D; Ozçakar N; Mevsim V
    Pharm World Sci; 2006 Aug; 28(4):199-206. PubMed ID: 17066242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups.
    Rickard E; Ozieranski P
    PLoS One; 2021; 16(6):e0252551. PubMed ID: 34166396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of healthcare communications agencies in maintaining compliance when working with the pharmaceutical industry and healthcare professionals.
    Cairns A; Yarker YE
    Curr Med Res Opin; 2008 May; 24(5):1371-8. PubMed ID: 18384708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs?
    Hughes D; Williams-Jones B
    Healthc Policy; 2013 Aug; 9(1):52-64. PubMed ID: 23968674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-to-consumer communication on prescription only medicines via the internet in the Netherlands, a pilot study. Opinion of the pharmaceutical industry, patient associations and support groups.
    Fabius AM; Cheung KC; Rijcken CJ; Vinkers CH; Talsma H
    Pharm World Sci; 2004 Jun; 26(3):169-72. PubMed ID: 15230365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.